{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:46:05Z","timestamp":1789785965914,"version":"4.0.1"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T00:00:00Z","timestamp":1424131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0117573","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T18:54:06Z","timestamp":1424199246000},"page":"e0117573","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Spred2 Modulates the Erythroid Differentiation Induced by Imatinib in Chronic Myeloid Leukemia Cells"],"prefix":"10.1371","volume":"10","author":[{"given":"Yuefeng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuya","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,2,17]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/leu.2010.101","article-title":"BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase\/blast crisis CML patients","volume":"24","author":"M Marega","year":"2010","journal-title":"Leukemia"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1385\/SCR:1:3:197","article-title":"Leukemia: stem cells, maturation arrest, and differentiation therapy","volume":"1","author":"S Sell","year":"2005","journal-title":"Stem Cell Rev"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"BJ Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1586\/17474086.2013.835697","article-title":"The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment","volume":"6","author":"N Jain","year":"2013","journal-title":"Expert Rev Hematol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00432-013-1488-z","article-title":"The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients","volume":"139","author":"A Hochhaus","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.seminhematol.2010.06.005","article-title":"Resistance to imatinib: mutations and beyond","volume":"47","author":"P La Rosee","year":"2010","journal-title":"Semin Hematol"},{"key":"ref7","first-page":"395","article-title":"Multivariate analysis of imatinib resistance-related factors during the treatment of chronic myeloid leukemia","volume":"34","author":"M Zhou","year":"2013","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia","volume":"15","author":"D Milojkovic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","article-title":"Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options","volume":"13","author":"EJ Jabbour","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/sj.leu.2403916","article-title":"Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant","volume":"19","author":"Q Wang","year":"2005","journal-title":"Leukemia"},{"key":"ref11","first-page":"944","article-title":"Induction of megakaryocytic differentiation in chronic myelogenous leukemia cell K562 by 3-hydrogenkwadaphnin","volume":"40","author":"A Meshkini","year":"2007","journal-title":"J Biochem Mol Biol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4161\/cbt.10.5.12584","article-title":"Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein","volume":"10","author":"L Yin","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bcp.2010.10.013","article-title":"Sustained exposure to the DNA demethylating agent, 2'-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy","volume":"81","author":"M Schnekenburger","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/onc.2012.246","article-title":"MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.)","volume":"32","author":"MT Gomez-Casares","year":"2013","journal-title":"Oncogene"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1096\/fj.03-0322fje","article-title":"Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage","volume":"17","author":"A Jacquel","year":"2003","journal-title":"FASEB J"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/sj.leu.2404690","article-title":"Signal transduction pathways that contribute to myeloid differentiation","volume":"21","author":"MB Miranda","year":"2007","journal-title":"Leukemia"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.bbrc.2010.02.044","article-title":"Spred2 is involved in imatinib-induced cytotoxicity in chronic myeloid leukemia cells","volume":"393","author":"XY Liu","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/CAD.0b013e32834a099c","article-title":"Methyl-beta-cyclodextrin induces programmed cell death in chronic myeloid leukemia cells and, combined with imatinib, produces a synergistic downregulation of ERK\/SPK1 signaling","volume":"23","author":"J Yan","year":"2012","journal-title":"Anticancer Drugs"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e23720","DOI":"10.1371\/journal.pone.0023720","article-title":"Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK\/ERK\/JNK and JAK2\/STAT3 \/AKT signalings","volume":"6","author":"J Zhu","year":"2011","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccr.2011.11.004","article-title":"Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia","volume":"20","author":"LM Packer","year":"2011","journal-title":"Cancer Cell"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/35088082","article-title":"Spred is a Sprouty-related suppressor of Ras signalling","volume":"412","author":"T Wakioka","year":"2001","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1038\/sj.onc.1207759","article-title":"The Sprouty-related protein, Spred, inhibits cell motility, metastasis, and Rho-mediated actin reorganization","volume":"23","author":"K Miyoshi","year":"2004","journal-title":"Oncogene"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1002\/ijc.25542","article-title":"Expression and functional role of negative signalling regulators in tumour development and progression","volume":"127","author":"T Murphy","year":"2010","journal-title":"Int J Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1038\/sj.onc.1209635","article-title":"Spreds, inhibitors of the Ras\/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors","volume":"25","author":"T Yoshida","year":"2006","journal-title":"Oncogene"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1084\/jem.20030830","article-title":"Spred-2 suppresses aorta-gonad-mesonephros hematopoiesis by inhibiting MAP kinase activation","volume":"199","author":"I Nobuhisa","year":"2004","journal-title":"J Exp Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.onc.1208421","article-title":"Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells","volume":"24","author":"A Essafi","year":"2005","journal-title":"Oncogene"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/leu.2008.186","article-title":"Acetylation of FOXO3a transcription factor in response to imatinib of chronic myeloid leukemia","volume":"23","author":"P Corrado","year":"2009","journal-title":"Leukemia"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"K Naka","year":"2010","journal-title":"Nature"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1074\/jbc.M606669200","article-title":"FOXO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1","volume":"282","author":"KU Birkenkamp","year":"2007","journal-title":"J Biol Chem"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1182\/blood-2008-05-159848","article-title":"FoxO3a regulates hematopoietic homeostasis through a negative feedback pathway in conditions of stress or aging","volume":"112","author":"K Miyamoto","year":"2008","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood.V99.4.1388","article-title":"Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2","volume":"99","author":"JF Dorsey","year":"2002","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/jcb.20407","article-title":"Fast apoptosis and erythroid differentiation induced by imatinib mesylate in JURL-MK1 cells","volume":"95","author":"K Kuzelova","year":"2005","journal-title":"J Cell Biochem"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"e61939","DOI":"10.1371\/journal.pone.0061939","article-title":"Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation","volume":"8","author":"YL Lee","year":"2013","journal-title":"PLoS One"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1023\/B:MCBI.0000012830.96393.b9","article-title":"Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it","volume":"258","author":"T Kawano","year":"2004","journal-title":"Mol Cell Biochem"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1271\/bbb.80483","article-title":"Induction of differentiation in k562 cell line by nicotinic acid-related compounds","volume":"73","author":"C Ida","year":"2009","journal-title":"Biosci Biotechnol Biochem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cellbi.2004.03.009","article-title":"ERK signaling pathway is differentially involved in erythroid differentiation of K562 cells depending on time and the inducing agent","volume":"28","author":"W Woessmann","year":"2004","journal-title":"Cell Biol Int"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/sj.leu.2403764","article-title":"Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL\u2014Inhibition of P-glycoprotein function by 17-AAG","volume":"19","author":"A Radujkovic","year":"2005","journal-title":"Leukemia"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2002-01-0043","article-title":"The effects of Bcr-Abl on C\/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate","volume":"101","author":"C Schuster","year":"2003","journal-title":"Blood"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0117573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T02:20:58Z","timestamp":1540347658000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0117573"}},"subtitle":[],"editor":[{"given":"Jingxuan","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,2,17]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,2,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0117573","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,17]]}}}